Alnylam Pharmaceuticals Inc (ALNY)vsCompugen (CGEN)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
CGEN
Compugen
$2.07
-0.96%
HEALTHCARE · Cap: $198.49M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 5004% more annual revenue ($3.71B vs $72.76M). CGEN leads profitability with a 48.6% profit margin vs 8.5%. CGEN trades at a lower P/E of 5.5x. CGEN earns a higher WallStSmart Score of 71/100 (B).
ALNY
Hold49
out of 100
Grade: D+
CGEN
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+33.7%
Fair Value
$2.58
Current Price
$2.07
$0.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Attractively priced relative to earnings
Every $100 of equity generates 45 in profit
Keeps 49 of every $100 in revenue as profit
Strong operational efficiency at 83.2%
Revenue surging 44.8% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : CGEN
The strongest argument for CGEN centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 48.6% and operating margin at 83.2%. Revenue growth of 44.8% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : CGEN
The primary concerns for CGEN are EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while CGEN is a growth play — different risk/reward profiles.
CGEN carries more volatility with a beta of 2.96 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
CGEN scores higher overall (71/100 vs 49/100), backed by strong 48.6% margins and 44.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compugen
HEALTHCARE · BIOTECHNOLOGY · USA
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?